Another strategy to improve anti-tumor immune responses by DC-derived EVs, based on previous observations of increased immunostimulatory properties by IFN-γ DC-derived exosomes [95], was elaborated in a Phase II clinical trial where EVs were derived from IFN-γ stimulated DC loaded with MHC class I- and II-restricted cancer antigens [127]. The gene discussed is IFNG; the disease is neoplasm.